Is ZVRA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ZVRA. It does not provide personalized investment advice.

ZVRA (Zevra Therapeutics, Inc. Common Stock) Stock Analysis - Financials

Zevra Therapeutics, Inc. Common Stock (ZVRA) is a publicly traded Healthcare sector company. As of October 13, 2026, ZVRA trades at $10.42 with a market cap of $672.22M and a P/E ratio of 11.70. ZVRA moved -8.22% today. Year to date, ZVRA is +24.58%; over the trailing twelve months it is -2.81%. Its 52-week range spans $6.19 to $15.04. Analyst consensus is strong buy with an average price target of $25.25. Rallies surfaces ZVRA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are ZVRA's key financials?

ZVRA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ZVRA recently traded at $10.42. Market cap is $672.22M. P/E ratio is 11.70. Revenue is $136.07M.

ZVRA Key Metrics

Key financial metrics for ZVRA
Metric	Value
Price	$10.42
Market Cap	$672.22M
P/E Ratio	11.70
EPS	$0.95
Dividend Yield	0.00%
52-Week High	$15.04
52-Week Low	$6.19
Volume	979.00K
Avg Volume	0
Revenue (TTM)	$136.07M
Net Income	$58.26M
Gross Margin	0.00%

ZVRA Analyst Consensus

9 analysts cover ZVRA: 0 strong buy, 9 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.25.

Common questions about ZVRA

What are ZVRA's key financials?: ZVRA financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. ZVRA recently traded at $10.42. Market cap is $672.22M. P/E ratio is 11.70. Revenue is $136.07M.
Is ZVRA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ZVRA. It does not provide personalized investment advice.